Skip to main content
Ajooni Biotech Limited logo

Ajooni Biotech Limited — Investor Relations & Filings

Ticker · AJOONI ISIN · INE820Y01021 LEI · 335800OAKJWKHF49O339 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 562 across all filing types
Latest filing 2024-08-09 Regulatory Filings
Country IN India
Listing National Stock Exchange of India AJOONI

About Ajooni Biotech Limited

https://www.ajoonibiotech.com

Ajooni Biotech Limited specializes in the production and distribution of animal healthcare solutions and nutritional supplements. The company focuses on the livestock sector, offering a comprehensive range of products including compounded cattle feed, mineral mixtures, and specialized supplements formulated to enhance milk productivity and overall animal health. Its portfolio features calcium supplements, liver tonics, and digestive aids designed to meet the specific nutritional needs of dairy animals. The company utilizes research-driven formulations and quality-controlled manufacturing processes to provide effective solutions for livestock management. By prioritizing animal welfare and productivity, it supports the operational efficiency of dairy farming through scientifically developed nutritional interventions.

Recent filings

Filing Released Lang Actions
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement on deviation or variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It specifically addresses the utilization of proceeds from a Right Issue for the quarter ended June 30, 2024. The document includes detailed tables showing original allocation, modified allocation, funds utilized, and deviations, and it is signed by the Managing Director. There is no indication that this is a full financial report or an earnings release; rather, it is a regulatory compliance statement related to fund utilization and deviations. This type of document fits the category of Regulatory Filings (RNS), as it is a regulatory announcement and compliance disclosure rather than a full financial report or other specific filing type.
2024-08-09 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication addressed to the National Stock Exchange of India, dated August 9, 2024. It announces the approval of un-audited financial results for the quarter ended June 30, 2024, by the Board of Directors. The document includes detailed financial data such as revenue, expenses, profit/loss figures, and other financial metrics for the quarter. It also mentions the inclusion of a Limited Review Report from the auditor for the same period. The presence of comprehensive financial statements and analysis for a quarter, along with auditor review, clearly indicates this is a quarterly financial report. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-09 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication from Ajooni Biotech Limited to the National Stock Exchange of India, dated August 9, 2024. It announces the outcome of a Board Meeting held on the same day, specifically mentioning the approval of "Un-audited Financial Results for the quarter ended June 30, 2024" and the accompanying Limited Review Report from the auditor. The document includes detailed financial data for the quarter ended June 30, 2024, such as revenue, expenses, and profit figures, indicating substantive financial information rather than a mere announcement or summary. The presence of unaudited quarterly financial results and a limited review report aligns with the characteristics of an Interim / Quarterly Report (IR). The document is approximately 15,000 characters long, which is consistent with a comprehensive financial report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-08-09 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice from Ajooni Biotech Limited addressed to the National Stock Exchange of India, informing about a scheduled Board Meeting on August 9, 2024. The agenda includes approval of unaudited financial results for the quarter ended June 30, 2024. The document is short (1759 characters) and serves as an announcement of an upcoming board meeting rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a transcript or report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about a board meeting and financial results approval date, not the results themselves or a detailed report.
2024-08-01 English
Board Meeting — AJOONI BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 09-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for th…
Regulatory Filings
2024-08-01 English
Press Release
Capital/Financing Update Classification · 85% confidence The document is a company announcement dated July 23, 2024, about Ajooni Biotech Limited entering the B2C Gujarat market for pure veg cattle feed. It includes some financial highlights for FY 2023-24 and projections for FY 2024-25, but it does not contain detailed financial statements or comprehensive financial analysis. The text is promotional and strategic in nature, focusing on market expansion and business updates rather than reporting full financial results or detailed management discussion. The document length is 4593 characters, which is relatively short and more consistent with a press release or capital/financing update rather than a full annual or interim report. There is no indication of it being a call transcript, AGM material, or regulatory filing. The content aligns best with a Capital/Financing Update (CAP) as it announces a significant business expansion and market entry, which can impact the company's capital and revenue prospects.
2024-07-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.